Kaiser Permanente Data Key to Nation’s COVID-19 Vaccine Surveillance Strategy
New vaccines recently approved to protect against COVID-19 disease were developed at record speed. To support public confidence in the […]
The COVAS Tool: Kaiser Permanente Southern California Develops Tool to Predict Outcomes for COVID-19 in Emergency Dept. Setting
Kaiser Permanente Southern California Department of Research & Evaluation has developed a COVID-19 risk assessment factoring in a number of […]
Epic-based Patient Registry Scales out to Support External Researchers: Kaiser Permanente’s Alcohol Use Patient Registry
With the pervasive use of electronic health record (EHR) data comes the opportunity to organize, aggregate, analyze, and even predictive […]
Study Suggests Majority of Rituximab Use Is Off Label
The term “off-label” is described by the FDA as an unapproved use of an approved drug. Recently, a study conducted […]
Some Data Points Lead to Possible Good Signs for Remdesivir, but Still Too Early to Tell
A growing number of healthcare professionals become optimistic about Gilead’s remdesivir as a possible treatment to at least slow down […]
Kaiser Permanente Participates Pathbreaking Study to Better Understand Genetics of Near Sightedness
Kaiser Permanente investigators are looking into the underlying genetic factors behind near-sightedness or myopia. The team has closed in on […]
Kaiser Permanente Research Reveals Depressed Pregnant Women Eating Poorly Putting Themselves and Future Children at Risk
A Kaiser Permanente Division of Research study revealed that pregnant women with depression are far more likely to eat poor […]
Kaiser Permanente Division of Research Real-World Study Impacts Changes to Hepatitis C Guidelines
A Kaiser Permanente Division of Research (DOR) real-world observational study has impacted new practice guidelines from the Infectious Diseases Society of […]
Kaiser Permanente Research Study Reveals Mastectomy Patients Can Recover Safely at Home
A recent Kaiser Permanente Research study, across 21 Kaiser sites in Northern California, reinforces a growing movement toward sending mastectomy […]
Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib
Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in […]
